Altimmune, Inc.

ALT · Nasdaq · SIC 2834: Pharmaceutical Preparations
318
SEC Filings

Business Summary

Altimmune, Inc. is a late clinical-stage biopharmaceutical company developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in clinical development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). As of December 31, 2025, over 700 patients have been exposed to pemvidutide across 8 completed and 2 ongoing clinical studies.

Next Earnings

Q2 FY2026 — expected 2026-09-19

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionALTdiscussed_in_filing Artificial Intelligence
topic_mentionALTdiscussed_in_filing Cybersecurity
topic_mentionALTdiscussed_in_filing Trusted Computing
topic_mentionALTdiscussed_in_filing Blockchain & Crypto
topic_mentionALTdiscussed_in_filing Supply Chain
topic_mentionALTdiscussed_in_filing Regulation
topic_mentionALTdiscussed_in_filing Automotive
topic_mentionALTdiscussed_in_filing Healthcare & Bio
topic_mentionALTdiscussed_in_filing Sovereign & Government
topic_mentionALTdiscussed_in_filing Artificial Intelligence
topic_mentionALTdiscussed_in_filing Cybersecurity
topic_mentionALTdiscussed_in_filing Trusted Computing
topic_mentionALTdiscussed_in_filing Blockchain & Crypto
topic_mentionALTdiscussed_in_filing Supply Chain
topic_mentionALTdiscussed_in_filing Regulation
topic_mentionALTdiscussed_in_filing Automotive
topic_mentionALTdiscussed_in_filing Healthcare & Bio
topic_mentionALTdiscussed_in_filing Sovereign & Government
topic_mentionALTdiscussed_in_filing Artificial Intelligence
topic_mentionALTdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-062025-12-310001326190-26-000018EDGAR79K words
2025-02-272024-12-310001326190-25-000015EDGAR—
2024-03-272023-12-310001326190-24-000010EDGAR—
2023-02-282022-12-310001326190-23-000008EDGAR—
2022-03-152021-12-310001558370-22-003659EDGAR—
2021-02-252020-12-310001564590-21-008422EDGAR—
2020-03-272019-12-310001564590-20-013377EDGAR—
2019-04-012018-12-310001564590-19-010429EDGAR—
2018-04-022017-12-310001193125-18-103623EDGAR—
2017-03-142016-12-310001144204-17-014528EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001326190-25-000064EDGAR16K words
2025-08-122025-06-300001326190-25-000040EDGAR—
2025-05-132025-03-310001326190-25-000034EDGAR—
2024-11-122024-09-300001326190-24-000050EDGAR—
2024-08-082024-06-300001326190-24-000030EDGAR—
2024-05-092024-03-310001326190-24-000019EDGAR—
2023-11-072023-09-300001326190-23-000047EDGAR—
2023-08-102023-06-300001326190-23-000036EDGAR—
2023-05-112023-03-310001326190-23-000028EDGAR—
2022-11-102022-09-300001326190-22-000013EDGAR—
2022-08-112022-06-300001558370-22-013271EDGAR—
2022-05-122022-03-310001558370-22-008535EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-050001326190-26-000013EDGAR3K words
2026-02-030001326190-26-000008EDGAR—
2026-01-280001326190-26-000006EDGAR—
2025-12-190001104659-25-122724EDGAR—
2025-12-010001104659-25-117144EDGAR—
2025-11-060001326190-25-000067EDGAR—
2025-11-060001326190-25-000055EDGAR—
2025-10-030001326190-25-000053EDGAR—
2025-09-250001326190-25-000050EDGAR—
2025-08-120001558370-25-011145EDGAR—

318 total filings indexed. 286 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

metabolic-dysfunction-associated-steatohepatitis-(mash) alcohol-use-disorder-(aud) alcohol-associated-liver-disease-(ald) metabolic-dysfunction-associated-liver-disease-(masld)

Company Identity

CIK0001326190
TickerALT
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 573c41c97eb67264f72dbd566a90898e973b94e77bb3eb01915504910c514a86
parent: 59f5b8c85c987feef5dc74ff18aafcdb1f85afc6581e8e0c913d0ce65c4c5c60
content hash: dd4c48b4ce0088bf1089d359439d3bcc11bb1c2b2f41819eafe55d9226b9d01b
signed: 2026-04-13T04:43:36.331Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf